In this comprehensive and well-structured review, Ragheb[
1] delves into the rising interest in intracavernosal platelet-rich plasma (PRP) therapy for erectile dysfunction (ED), an area where clinical curiosity has outpaced standardization. With increasing attention on regenerative urology, this article provides a timely overview of both preclinical and clinical data surrounding PRP as a novel, autologous, and biologically intuitive treatment strategy for ED.
The core message is clear: PRP shows promise—but the path to clinical integration remains fraught with variability. The author systematically presents the mechanism of action, preparation variability, and existing randomized controlled trials (RCTs). Importantly, the article emphasizes a crucial point: while biological plausibility and early results are encouraging, the field is hindered by heterogeneous study designs, inconsistent outcome reporting, and lack of long-term safety and efficacy data.
What distinguishes this review is its balance between optimism and scientific rigor. It does not merely catalog findings but critically reflects on methodological shortcomings, including variation in PRP concentrations, administration protocols, and follow-up durations. This underscores the challenge of drawing actionable conclusions from current literature.
In context, this review expands upon earlier exploratory work in PRP for ED[
2,
3] and confirms the same theme: we are at a promising, yet immature, stage in translating biologic therapies into reproducible interventions. Compared to the adoption of other regenerative modalities like low-intensity shockwave therapy, PRP still lacks consistent dosing protocols and reliable biomarkers of response.
However, a notable limitation is the scarcity of RCTs, with only five identified, which constrains the evidence base. This paucity has led many authors to rely on systematic reviews and meta-analyses, which, while valuable, are limited by the heterogeneity and small sample sizes of the underlying studies. This trend underscores the urgent need for more robust RCTs to establish PRP's efficacy.
Future directions, as aptly noted by the author, must include multicenter RCTs with clearly defined inclusion criteria, PRP system calibration, and long-term endpoints. Moreover, exploring synergy with adjunct therapies (e.g., PDE5 inhibitors or shockwave therapy) may help overcome responder variability.
2025 The Author(s). UroPrecision published by John Wiley & Sons Australia, Ltd on behalf of Higher Education Press.
PDF
(64KB)
